Imperial College London

Dr Shivani Misra

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction




+44 (0)20 7594 6136s.misra




G4Medical SchoolSt Mary's Campus





Consultant in Metabolic Medicine & Honorary Senior Clinical Lecturer

Dr Shivani Misra is a Consultant Physician in Diabetes & Metabolic Medicine  at Imperial College Healthcare NHS Trust and an Honorary Senior Clinical Lecturer within Imperial College London. 

Dr Misra leads a portfolio of studies that investigate the genetics, epidemiology, classification and treatment of early-onset type 2 diabetes, defined as a diagnosis of type 2 diabetes in childhood or early-adulthood (<40 years).

As of 2022 she will be a Wellcome Trust Career Development Fellow having been awarded this prestigious 5-year fellowship to investigate early-onset type 2 diabetes.

Dr Misra was awarded a Future Leaders Mentorship Award from the European Federation for the Study of Diabetes (2017) and in 2021 was awarded a QiC award from NHS England for contributions to diabetes research / services

Selected active studies:

A person diagnosed with type 2 diabetes at young age has a higher risk for the development of diabetes complications than later-onset type 2 diabetes and, unfortunately, large studies show that they do not live as long as people who are diagnosed later in life. The factors that drive these concerning outcomes, remain unclear.  Dr Misra and her team are investigating this clinical problem in a portfolio of studies:

1) Wellcome Trust funded study investigating the genetics and epidemiology of early-onset type 2 diabetes in south Asian individuals 

2) NIHR funded collaborative study (M3 programme) developing an holistic multi-modal intervention for adults with early-onset type 2 diabetes, tested through qualitative patient-reported outcomes and quantitative microvascular and glucose outcomes in an RCT.

3) Diabetes UK funded study that will investigate the use of prediction models to segregate early-onset type 2 diabetes from other forms of diabetes including monogenic and type 1 diabetes, in south Asian and African-Caribbean individuals with early-onset diabetes.

4) Diabetes UK funded studentship (collaborative with Professor Guy Rutter) to investigate the effect of rare MODY mutations on iPSC-derived pancreatic beat-cells from human fibroblasts (DiPS study).

"Using genetic, epidemiological and interventional studies, we are working to discover the best way to detect, classify and treat people with early-onset type 2 diabetes from all ethnic backgrounds" Dr Shivani Misra


During her Doctoral project, Dr Misra set up the MY DIABETES study, which has recruited almost 1800 individuals over 40 hospitals around England. The MY DIABETES study aimed to phenotype young-onset diabetes in south Asian and African-Caribbean ethnicities in the UK. Her core research interest focuses on stratifying young-onset diabetes using biomarkers and genetics to improve treatment and identification of young-onset diabetes types.

Prior to her Doctoral work, Shivani was an NIHR Academic Clinical Fellow in metabolic medicine &  chemical pathology and completed a PhD in the Section of Diabetes, Endocrinology & Metabolism, funded by a Sutherland-Earl Clinical Research Fellowship from the Diabetes Research and Wellness Foundation.

She has trained in diabetes, clinical biochemistry and laboratory medicine and is a Fellow of the Royal College of Pathologists and Member of the Royal College of Physicians.

Other activities: 

  1. Co-Chair of the American Diabetes Association Precision Medicine Working group on precision diagnostics for type 2 diabetes

2. Trustee of the Diabetes Research & Wellness Foundation, diabetes charity

3. Conference organising committee member, Diabetes UK 2020-2023

4. Member of the young-onset type 2 diabetes NHS Digital National Diabetes audit working group 2021

5. Member of the NDISA (NADIA - Harms) strategy group, NHS Digital, National Diabetes Audit

6. North Thames GMSA Lead for monogenic diabetes



Misra S, Florez JC, 2022, Extending precision medicine tools to populations at high risk of type 2 diabetes., Plos Med, Vol:19

Eng PC, Distaso W, Durreshahwar H, et al., 2022, The benefit of dexamethasone in patients with COVID-19 infection is preserved in patients with diabetes., Diabetes, Obesity and Metabolism: a Journal of Pharmacology and Therapeutics, Vol:24, ISSN:1462-8902, Pages:1385-1389

Thomas NJ, Dennis JM, Sharp SA, et al., 2021, DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life (vol 64, pg 2258, 2021), Diabetologia, Vol:65, ISSN:0012-186X, Pages:258-258

Misra S, Barron E, Vamos E, et al., 2021, Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study, The Lancet Diabetes and Endocrinology, ISSN:2213-8595

Grace SL, Bowden J, Walkey HC, et al., 2021, Islet autoantibody level distributions in type 1 diabetes and their association with genetic and clinical characteristics

More Publications